Top

Published in:

01-06-2017 | Review

Cardiovascular risk in patients with rheumatoid arthritis

Authors: Kim Lauper, Cem Gabay

Published in: Seminars in Immunopathology | Issue 4/2017

Abstract

Substantial epidemiologic data have shown an increased risk of cardiovascular (CV) disease in rheumatoid arthritis (RA) patients. Traditional CV risk factors may partly contribute to CV disease in RA; however, current evidence underlines the important role of inflammation in the pathogenesis of atherosclerosis and amplification of CV risk. Interplays between inflammation and lipid metabolism in the development of atherosclerosis have been established by recent scientific advances. Atherosclerosis is currently viewed as an inflammatory disease, and modifications of lipoproteins during inflammation accelerate atherogenesis. The role of inflammation in the increased CV risk in RA has been further demonstrated by the CV protective effect of methotrexate and TNF antagonists, particularly in patients responding to these treatments. The management of CV risk in RA should include the use of effective disease-modifying anti-rheumatic drugs to control disease activity and the treatment of traditional CV risk factors.

Cobb S, Anderson F, Bauer W (1953) Length of life and cause of death in rheumatoid arthritis. N Engl J Med 249:553–556. doi:10.1056/NEJM195310012491402 PubMedCrossRef

Wolfe F, Mitchell DM, Sibley JT et al (1994) The mortality of rheumatoid arthritis. Arthritis Rheum 37:481–494. doi:10.1002/art.1780370408 PubMedCrossRef

Gabriel SE, Crowson CS, Kremers HM et al (2003) Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 48:54–58. doi:10.1002/art.10705 PubMedCrossRef

Doran MF, Crowson CS, Pond GR et al (2002) Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 46:2287–2293. doi:10.1002/art.10524 PubMedCrossRef

Mellemkjaer L, Linet MS, Gridley G et al (1996) Rheumatoid arthritis and cancer risk. Eur J Cancer 32A:1753–1757. doi:10.1016/0959-8049(96)00210-9 PubMedCrossRef

Bongartz T, Nannini C, Medina-Velasquez YF et al (2010) Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum 62:1583–1591. doi:10.1002/art.27405 PubMedPubMedCentralCrossRef

Solomon DH, Karlson EW, Rimm EB et al (2003) Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107:1303–1307. doi:10.1161/01.CIR.0000054612.26458.B2 PubMedCrossRef

Aviña-Zubieta JA, Choi HK, Sadatsafavi M et al (2008) Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 59:1690–1697. doi:10.1002/art.24092 PubMedCrossRef

Kremers HM, Crowson CS, Therneau TM et al (2008) High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population-based cohort study. Arthritis Rheum 58:2268–2274. doi:10.1002/art.23650 PubMedCrossRef

10.

Holmqvist ME, Wedrén S, Jacobsson LTH et al (2009) No increased occurrence of ischemic heart disease prior to the onset of rheumatoid arthritis: results from two Swedish population-based rheumatoid arthritis cohorts. Arthritis Rheum 60:2861–2869. doi:10.1002/art.24855 PubMedCrossRef

11.

Wilson PW (1994) Established risk factors and coronary artery disease: the Framingham study. Am J Hypertens 7:7S–12SPubMedCrossRef

12.

Panoulas VF, Douglas KMJ, Milionis HJ et al (2007) Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology (Oxford) 46:1477–1482. doi:10.1093/rheumatology/kem169 CrossRef

13.

Boyer J-F, Gourraud P-A, Cantagrel A et al (2011) Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. Joint Bone Spine 78:179–183. doi:10.1016/j.jbspin.2010.07.016 PubMedCrossRef

14.

Solomon DH, Curhan GC, Rimm EB et al (2004) Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthritis Rheum 50:3444–3449. doi:10.1002/art.20636 PubMedCrossRef

15.

Gonzalez A, Maradit Kremers H, Crowson CS et al (2008) Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann Rheum Dis 67:64–69. doi:10.1136/ard.2006.059980 PubMedCrossRef

16.

Metsios GS, Stavropoulos-Kalinoglou A, Panoulas VF et al (2009) Association of physical inactivity with increased cardiovascular risk in patients with rheumatoid arthritis. Eur J Cardiovasc Prev Rehabil 16:188–194. doi:10.1097/HJR.0b013e3283271ceb PubMedCrossRef

17.

Panoulas VF, Metsios GS, Pace AV et al (2008) Hypertension in rheumatoid arthritis. Rheumatology (Oxford) 47:1286–1298. doi:10.1093/rheumatology/ken159 CrossRef

18.

Ouchi N, Parker JL, Lugus JJ, Walsh K (2011) Adipokines in inflammation and metabolic disease. Nat Rev Immunol 11:85–97. doi:10.1038/nri2921 PubMedPubMedCentralCrossRef

19.

Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR et al (2010) Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-alpha therapy. Ann N Y Acad Sci 1193:153–159. doi:10.1111/j.1749-6632.2009.05287.x PubMedCrossRef

20.

Giles JT, Danielides S, Szklo M et al (2015) Insulin resistance in rheumatoid arthritis: disease-related indicators and associations with the presence and progression of subclinical atherosclerosis. Arthritis Rheumatol (Hoboken, NJ) 67:626–636. doi:10.1002/art.38986 CrossRef

21.

Stavropoulos-Kalinoglou A, Metsios GS, Panoulas VF et al (2012) Anti-tumour necrosis factor alpha therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis. Arthritis Res Ther 14:R160. doi:10.1186/ar3900 PubMedPubMedCentralCrossRef

22.

Klareskog L, Stolt P, Lundberg K et al (2006) A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 54:38–46. doi:10.1002/art.21575 PubMedCrossRef

23.

Papadopoulos NG, Alamanos Y, Voulgari PV et al (2005) Does cigarette smoking influence disease expression, activity and severity in early rheumatoid arthritis patients? Clin Exp Rheumatol 23(6):861–866PubMed

24.

Saag KG, Cerhan JR, Kolluri S et al (1997) Cigarette smoking and rheumatoid arthritis severity. Ann Rheum Dis 56:463–469. doi:10.1136/ard.56.8.463 PubMedPubMedCentralCrossRef

25.

Hyrich KL, Watson KD, Silman AJ et al (2006) Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 45:1558–1565. doi:10.1093/rheumatology/kel149 CrossRef

26.

Saevarsdottir S, Wedrén S, Seddighzadeh M et al (2011) Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the epidemiological investigation of rheumatoid arthritis and the Swedish Rheumatology Reg. Arthritis Rheum 63:26–36. doi:10.1002/art.27758 PubMedCrossRef

27.

Kaushik P, Solomon DH, Greenberg JD et al (2015) Subcutaneous nodules are associated with cardiovascular events in patients with rheumatoid arthritis: results from a large US registry. Clin Rheumatol 34:1697–1704. doi:10.1007/s10067-015-3032-9 PubMedCrossRef

28.

Ljung L, Rantapää-Dahlqvist S, Jacobsson LTH, et al (2016) Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis. Ann Rheum Dis annrheumdis-2015-208995. doi: 10.1136/annrheumdis-2015-208995

29.

Solomon DH, Reed GW, Kremer JM et al (2015) Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol (Hoboken, NJ) 67:1449–1455. doi:10.1002/art.39098 CrossRef

30.

Goodson NJ, Wiles NJ, Lunt M et al (2002) Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 46:2010–2019. doi:10.1002/art.10419 PubMedCrossRef

31.

López-Longo FJ, Oliver-Miñarro D, de la Torre I et al (2009) Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum 61:419–424. doi:10.1002/art.24390 PubMedCrossRef

32.

Homocysteine Studies Collaboration (2002) Homocysteine and risk of ischemic heart disease and stroke. JAMA 288:2015. doi:10.1001/jama.288.16.2015 CrossRef

33.

Klerk M, Verhoef P, Clarke R et al (2002) MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 288:2023–2031PubMedCrossRef

34.

Lonn E, Yusuf S, Arnold MJ et al (2006) Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354:1567–1577. doi:10.1056/NEJMoa060900 PubMedCrossRef

35.

van Ede AE, Laan RFJM, Blom HJ et al (2002) Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology (Oxford) 41:658–665. doi:10.1093/rheumatology/41.6.658 CrossRef

36.

Calle EE, Thun MJ, Petrelli JM et al (1999) Body-mass index and mortality in a prospective cohort. N Engl J Med 341:1097–1105PubMedCrossRef

37.

Després JP (2012) Body fat distribution and risk of cardiovascular disease: an update. Circulation 126:1301–1313. doi:10.1161/CIRCULATIONAHA.111.067264 PubMedCrossRef

38.

Kremers HM, Nicola PJ, Crowson CS et al (2004) Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum 50:3450–3457. doi:10.1002/art.20612 PubMedCrossRef

39.

Giles JT, Allison M, Blumenthal RS et al (2010) Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics. Arthritis Rheum 62:3173–3182. doi:10.1002/art.27629 PubMedPubMedCentralCrossRef

40.

Walsmith J, Roubenoff R (2002) Cachexia in rheumatoid arthritis. Int J Cardiol 85:89–99. doi:10.1016/S0167-5273(02)00237-1 PubMedCrossRef

41.

Rajbhandary R, Khezri A, Panush RS (2011) Rheumatoid cachexia: what is it and why is it important? J Rheumatol 38:406–408. doi:10.3899/jrheum.101036 PubMedCrossRef

42.

Souverein PC, Berard A, Van Staa TP et al (2004) Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart 90:859–865. doi:10.1136/hrt.2003.020180 PubMedPubMedCentralCrossRef

43.

Coxib and traditional NSAID Trialists’ (CNT) Collaboration, Bhala N, Emberson J et al (2013) Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382:769–779. doi:10.1016/S0140-6736(13)60900-9 CrossRef

44.

Verhoeven F, Prati C, Maguin-Gaté K et al (2016) Glucocorticoids and endothelial function in inflammatory diseases: focus on rheumatoid arthritis. Arthritis Res Ther 18:258. doi:10.1186/s13075-016-1157-0 PubMedPubMedCentralCrossRef

45.

del Rincón I, Battafarano DF, Restrepo JF et al (2014) Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheumatol (Hoboken, NJ) 66:264–272. doi:10.1002/art.38210 CrossRef

46.

Choy E, Sattar N (2009) Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 68:460–469. doi:10.1136/ard.2008.101964 PubMedCrossRef

47.

Robertson J, Peters MJ, McInnes IB, Sattar N (2013) Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat Rev Rheumatol 9:513–523. doi:10.1038/nrrheum.2013.91 PubMedCrossRef

48.

van Gameren MM, Willemse PH, Mulder NH et al (1994) Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood 84:1434–1441PubMed

49.

Kremer J, Genovese MC, Keystone E et al (2016) Effects of baricitinib on lipid, apolipoprotein, and lipoprotein particle profiles in a phase 2b study in patients with active rheumatoid arthritis. Arthritis Rheumatol (Hoboken, NJ) 11:300–308. doi:10.1002/art.40036

50.

del Rincón ID, Williams K, Stern MP et al (2001) High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44:2737–2745. doi:10.1002/1529-0131(200112)44:12<2737::AID-ART460>3.0.CO;2-# PubMedCrossRef

51.

Skeoch S, Bruce IN (2015) Atherosclerosis in rheumatoid arthritis: is it all about inflammation? Nat Rev Rheumatol 11:1–11. doi:10.1038/nrrheum.2015.40 CrossRef

52.

Ridker PM, Buring JE, Shih J et al (1998) Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98:731–733PubMedCrossRef

53.

Zacho J, Tybjaerg-Hansen A, Jensen JS et al (2008) Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 359:1897–1908. doi:10.1056/NEJMoa0707402 PubMedCrossRef

54.

Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105:1135–1143. doi:10.1161/hc0902.104353 PubMedCrossRef

55.

Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685–1695. doi:10.1056/NEJMra043430 PubMedCrossRef

56.

Ross R (1999) Atherosclerosis—an inflammatory disease. N Engl J Med 340:115–126. doi:10.1016/S1053-0770(99)90233-1 PubMedCrossRef

57.

Libby P (2002) Inflammation in atherosclerosis. Nature 420:868–874. doi:10.1038/nature01323 PubMedCrossRef

58.

Deanfield JE, Halcox JP, Rabelink TJ (2007) Endothelial function and dysfunction: testing and clinical relevance. Circulation 115:1285–1295. doi:10.1161/CIRCULATIONAHA.106.652859 PubMed

59.

Libby P (2013) Mechanisms of acute coronary syndromes and their implications for therapy pathogenesis of acute coronary syndromes. N Engl J Med 36821368:2004–2013. doi:10.1056/NEJMra1216063 CrossRef

60.

Davignon J, Ganz P (2004) Role of endothelial dysfunction in atherosclerosis. Circulation 109:III27–III32. doi:10.1161/01.CIR.0000131515.03336.f8 PubMedCrossRef

61.

Wright HL, Moots RJ, Edwards SW (2014) The multifactorial role of neutrophils in rheumatoid arthritis. Nat Publ Gr 10:593–601. doi:10.1038/nrrheum.2014.80

62.

Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A et al (2013) NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci Transl Med 5:178ra40. doi:10.1126/scitranslmed.3005580 PubMedPubMedCentralCrossRef

63.

Döring Y, Soehnlein O, Weber C (2017) Neutrophil extracellular traps in atherosclerosis and atherothrombosis. Circ Res 120:736–743. doi:10.1161/CIRCRESAHA.116.309692 PubMedCrossRef

64.

Hannawi S, Haluska B, Marwick TH, Thomas R (2007) Atherosclerotic disease is increased in recent-onset rheumatoid arthritis: a critical role for inflammation. Arthritis Res Ther 9:R116. doi:10.1186/ar2323 PubMedPubMedCentralCrossRef

65.

Rho YH, Chung CP, Oeser A et al (2009) Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum 61:1580–1585. doi:10.1002/art.25009 PubMedPubMedCentralCrossRef

66.

National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and T of HBC in A (Adult TPI (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106:3143–3421. doi:10.1115/1.802915.ch1

67.

Khovidhunkit W, Kim M-S, Memon RA et al (2004) Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 45:1169–1196. doi:10.1194/jlr.R300019-JLR200 PubMedCrossRef

68.

Huang R, Silva RAGD, Jerome WG et al (2011) Apolipoprotein A-I structural organization in high-density lipoproteins isolated from human plasma. Nat Struct Mol Biol 18:416–422. doi:10.1038/nsmb.2028 PubMedPubMedCentralCrossRef

69.

Rosenson RS, Brewer HB, Chapman MJ et al (2011) HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem 57:392–410. doi:10.1373/clinchem.2010.155333 PubMedCrossRef

70.

Lüscher TF, Landmesser U, Von Eckardstein A, Fogelman AM (2014) High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target. Circ Res 114:171–182. doi:10.1161/CIRCRESAHA.114.300935 PubMedCrossRef

71.

Rosenson RS, Brewer HB, Davidson WS et al (2012) Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 125:1905–1919. doi:10.1161/CIRCULATIONAHA.111.066589 PubMedPubMedCentralCrossRef

72.

Kwiterovich PO (2000) The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: a current review. Am J Cardiol 86:5–10. doi:10.1016/S0002-9149(00)01461-2 CrossRef

73.

Esterbauer H, Gebicki J, Puhl H, Jürgens G (1992) The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med 13:341–390. doi:10.1016/0891-5849(92)90181-F PubMedCrossRef

74.

Segrest JP, Jones MK, De Loof H, Dashti N (2001) Structure of apolipoprotein B-100 in low density lipoproteins. J Lipid Res 42:1346–1367PubMed

75.

Berliner JA, Navab M, Fogelman AM et al (1995) Atherosclerosis: basic mechanisms. Circulation 91

76.

Steinberg D (2009) The LDL modification hypothesis of atherogenesis: an update. J Lipid Res 50 Suppl:S376–S381. doi:10.1194/jlr.R800087-JLR200 PubMed

77.

Bentzon JF, Otsuka F, Virmani R, Falk E (2014) Mechanisms of plaque formation and rupture. Circ Res 114:1852–1866. doi:10.1161/CIRCRESAHA.114.302721 PubMedCrossRef

78.

Kronenberg F, Kronenberg MF, Kiechl S et al (1999) Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation 100:1154–1160. doi:10.1161/01.CIR.100.11.1154 PubMedCrossRef

79.

Gabay C, McInnes IB, Kavanaugh A et al (2015) Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. Ann Rheum Dis. doi:10.1136/annrheumdis-2015-207872

80.

Mallat Z, Benessiano J, Simon T et al (2007) Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-NORFOLK study. Arterioscler Thromb Vasc Biol 27:1177–1183. doi:10.1161/ATVBAHA.107.139352 PubMedCrossRef

81.

Van Lenten BJ, Hama SY, Beer FC et al (1995) Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. J Clin Invest 96:2758–2767PubMedPubMedCentralCrossRef

82.

Durrington P, Mackness B, Mackness M (2001) Paraoxonase and atherosclerosis. Arter Thromb Vasc Biol 21:473–480. doi:10.1161/01.ATV.21.4.473 CrossRef

83.

Mackness B, Quarck R, Verreth W et al (2006) Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arterioscler Thromb Vasc Biol 26:1545–1550. doi:10.1161/01.ATV.0000222924.62641.aa PubMedCrossRef

84.

Bhattacharyya T, Nicholls SJ, Topol EJ et al (2008) Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 299:1265–1276. doi:10.1001/jama.299.11.1265 PubMedCrossRef

85.

Mackness MI, Arrol S, Durrington PN (1991) Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 286:152–154PubMedCrossRef

86.

Aviram M, Rosenblat M (2004) Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic Biol Med 37:1304–1316. doi:10.1016/j.freeradbiomed.2004.06.030 PubMedCrossRef

87.

Malmendier CL, Lontie JF, Sculier JP, Dubois DY (1988) Modifications of plasma lipids, lipoproteins and apolipoproteins in advanced cancer patients treated with recombinant interleukin-2 and autologous lymphokine-activated killer cells. Atherosclerosis 73:173–180. doi:10.1016/0021-9150(88)90039-1 PubMedCrossRef

88.

Kurzrock R, Rohde MF, Quesada JR et al (1986) Recombinant gamma interferon induces hypertriglyceridemia and inhibits post-heparin lipase activity in cancer patients. J Exp Med 164:1093–1101PubMedCrossRef

89.

Sherman ML, Spriggs DR, Arthur KA et al (1988) Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. JClinOncol 6:344–350CrossRef

90.

Starnes HF, Warren RS, Jeevanandam M et al (1988) Tumor necrosis factor and the acute metabolic response to tissue injury in man. J Clin Invest 82:1321–1325. doi:10.1172/JCI113733 PubMedPubMedCentralCrossRef

91.

Ansell BJ, Navab M, Hama S et al (2003) Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 108:2751–2756. doi:10.1161/01.CIR.0000103624.14436.4B PubMedCrossRef

92.

McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365:2205–2219. doi:10.1056/NEJMra1004965 PubMedCrossRef

93.

Tanimoto N, Kumon Y, Suehiro T et al (2003) Serum paraoxonase activity decreases in rheumatoid arthritis. Life Sci 72:2877–2885. doi:10.1016/S0024-3205(03)00195-4 PubMedCrossRef

94.

Charles-Schoeman C, Lee YY, Shahbazian A et al (2013) Association of paraoxonase 1 gene polymorphism and enzyme activity with carotid plaque in rheumatoid arthritis. Arthritis Rheum 65:2765–2772. doi:10.1002/art.38118 PubMedPubMedCentralCrossRef

95.

Charles-Schoeman C, Watanabe J, Lee YY et al (2009) Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum 60:2870–2879. doi:10.1002/art.24802 PubMedPubMedCentralCrossRef

96.

Liao KP, Playford MP, Frits M et al (2015) The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis. JAmHeart Assoc 4:1–8. doi:10.1161/JAHA.114.001588

97.

Boers M, Nurmohamed MT, Doelman CJA et al (2003) Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 62:842–845. doi:10.1136/ard.62.9.842 PubMedPubMedCentralCrossRef

98.

Charles-Schoeman C, Gonzalez-Gay MA, Kaplan I et al (2016) Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist. Semin Arthritis Rheum 46:71–80. doi:10.1016/j.semarthrit.2016.03.004 PubMedCrossRef

99.

Restrepo JF, del Rincon I, Molina E et al (2017) Use of hydroxychloroquine is associated with improved lipid profile in rheumatoid arthritis patients. J Clin Rheumatol. doi:10.1097/RHU.0000000000000502 PubMed

100.

Mackey RH, Kuller LH, Deane KD et al (2015) Rheumatoid arthritis, anti-cyclic citrullinated peptide positivity, and cardiovascular disease risk in the Women’s Health Initiative. Arthritis Rheumatol 67:2311–2322. doi:10.1002/art.39198 PubMedPubMedCentralCrossRef

101.

Ajeganova S, Huizinga TWJ (2015) Seronegative and seropositive RA: alike but different? Nat Rev Rheumatol 11:8–9. doi:10.1038/nrrheum.2014.194 PubMedCrossRef

102.

Vuilleumier N, Rossier MF, Pagano S et al (2010) Anti-apolipoprotein A-1 IgG as an independent cardiovascular prognostic marker affecting basal heart rate in myocardial infarction. Eur Heart J 31:815–823. doi:10.1093/eurheartj/ehq055 PubMedCrossRef

103.

Montecucco F, Vuilleumier N, Pagano S et al (2011) Anti-apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability. Eur Heart J 32:412–421. doi:10.1093/eurheartj/ehq521 PubMedCrossRef

104.

O’Neill SG, Giles I, Lambrianides A et al (2010) Antibodies to apolipoprotein A-I, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 62:845–854. doi:10.1002/art.27286 PubMedCrossRef

105.

Vuilleumier N, Bas S, Pagano S et al (2010) Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 62:2640–2650. doi:10.1002/art.27546 PubMedCrossRef

106.

Gonzalez-Gay MA, Gonzalez-Juanatey C, Lopez-Diaz MJ et al (2007) HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 57:125–132. doi:10.1002/art.22482 PubMedCrossRef

107.

Luepker RV, Apple FS, Christenson RH et al (2003) Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a statement from the AHA Council on epidemiology and prevention. Circulation 108:2543–2549. doi:10.1161/01.CIR.0000100560.46946.EA PubMedCrossRef

108.

Douglas KMJ, Pace AV, Treharne GJ et al (2006) Excess recurrent cardiac events in rheumatoid arthritis patients with acute coronary syndrome. Ann Rheum Dis 65:348–353. doi:10.1136/ard.2005.037978 PubMedCrossRef

109.

Maradit-Kremers H, Crowson CS, Nicola PJ et al (2005) Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 52:402–411. doi:10.1002/art.20853 PubMedCrossRef

110.

Mantel Ä, Holmqvist M, Jernberg T et al (2015) Rheumatoid arthritis is associated with a more severe presentation of acute coronary syndrome and worse short-term outcome. Eur Heart J 36:3413–3422. doi:10.1093/eurheartj/ehv461 PubMedCrossRef

111.

Zhao D, Liu J, Xie W, Qi Y (2015) Cardiovascular risk assessment: a global perspective. Nat Rev Cardiol 12:301–311. doi:10.1038/nrcardio.2015.28 PubMedCrossRef

112.

Crowson CS, Matteson EL, Roger VL et al (2012) Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. Am J Cardiol 110:420–424. doi:10.1016/j.amjcard.2012.03.044 PubMedPubMedCentralCrossRef

113.

Kawai VK, Chung CP, Solus JF et al (2015) Brief report: the ability of the 2013 American College of Cardiology/American Heart Association cardiovascular risk score to identify rheumatoid arthritis patients with high coronary artery calcification scores. Arthritis Rheumatol 67:381–385. doi:10.1002/art.38944 PubMedPubMedCentralCrossRef

114.

Arts EE, Popa C, Den Broeder AA et al (2015) Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis. Ann Rheum Dis 74:668–674. doi:10.1136/annrheumdis-2013-204024 PubMedCrossRef

115.

Mosca L, Benjamin EJ, Berra K et al (2011) Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the American Heart Association. Circulation 123:1243–1262. doi:10.1161/CIR.0b013e31820faaf8 PubMedPubMedCentralCrossRef

116.

Peters MJL, Symmons DPM, McCarey D et al (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69:325–331. doi:10.1136/ard.2009.113696 PubMedCrossRef

117.

Gómez-Vaquero C, Corrales A, Zacarías A et al (2013) SCORE and REGICOR function charts underestimate the cardiovascular risk in Spanish patients with rheumatoid arthritis. Arthritis Res Ther 15:R91. doi:10.1186/ar4271 PubMedPubMedCentralCrossRef

118.

Agca R, Heslinga SC, Rollefstad S, et al (2016) EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. 1–12. doi: 10.1136/annrheumdis-2016-209775

119.

Inaba Y, Chen JA, Bergmann SR et al (2011) Carotid intima-media thickness and cardiovascular events. N Engl J Med 365:1640–1641. 1640-2. doi:10.1056/NEJMc1109714#SA1 PubMedCrossRef

120.

del Rincón I, Polak JF, O’Leary DH et al (2015) Systemic inflammation and cardiovascular risk factors predict rapid progression of atherosclerosis in rheumatoid arthritis. Ann Rheum Dis 74:1118–1123. doi:10.1136/annrheumdis-2013-205058 PubMedCrossRef

121.

Semb AG, Rollefstad S, Provan SA et al (2013) Carotid plaque characteristics and disease activity in rheumatoid arthritis. J Rheumatol 40:359–368. doi:10.3899/jrheum.120621 PubMedCrossRef

122.

González-Juanatey C, Llorca J, González-Gay MA (2011) Correlation between endothelial function and carotid atherosclerosis in rheumatoid arthritis patients with long-standing disease. Arthritis Res Ther 13:R101. doi:10.1186/ar3382 PubMedPubMedCentralCrossRef

123.

Evans MR, Escalante A, Battafarano DF et al (2011) Carotid atherosclerosis predicts incident acute coronary syndromes in rheumatoid arthritis. Arthritis Rheum 63:1211–1220. doi:10.1002/art.30265 PubMedPubMedCentralCrossRef

124.

Corrales A, Parra JA, González-Juanatey C et al (2013) Cardiovascular risk stratification in rheumatic diseases: carotid ultrasound is more sensitive than coronary artery calcification score to detect subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis 72:1764–1770. doi:10.1136/annrheumdis-2013-203688 PubMedCrossRef

125.

Micha R, Imamura F, Wyler von Ballmoos M et al (2011) Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 108:1362–1370. doi:10.1016/j.amjcard.2011.06.054 PubMedPubMedCentralCrossRef

126.

Low ASL, Symmons DPM, Lunt M et al (2017) Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. Ann Rheum Dis. doi:10.1136/annrheumdis-2016-209784 PubMedCentral

127.

Desai SS, Myles JD, Kaplan MJ (2012) Suboptimal cardiovascular risk factor identification and management in patients with rheumatoid arthritis: a cohort analysis. Arthritis Res Ther 14:R270. doi:10.1186/ar4118 PubMedPubMedCentralCrossRef

128.

van den Oever IAM, Heslinga M, Griep EN, et al (2017) Cardiovascular risk management in rheumatoid arthritis patients still suboptimal: the Implementation of Cardiovascular Risk Management in Rheumatoid Arthritis project. Rheumatology 1–7. doi:10.1093/rheumatology/kew497

Title: Cardiovascular risk in patients with rheumatoid arthritis
Authors: Kim Lauper
Cem Gabay
Publication date: 01-06-2017
Publisher: Springer Berlin Heidelberg
Published in: Seminars in Immunopathology / Issue 4/2017
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI: https://doi.org/10.1007/s00281-017-0632-2

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Cardiovascular risk in patients with rheumatoid arthritis

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2017

Genetics of rheumatoid arthritis susceptibility, severity, and treatment response

Rheumatoid arthritis: from basic findings and clinical manifestations to future therapies

The role of autoantibodies in the pathophysiology of rheumatoid arthritis

Environmental factors and hormones in the development of rheumatoid arthritis

Synovial cellular and molecular markers in rheumatoid arthritis

Future therapeutic targets in rheumatoid arthritis?

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page